Efficacy of EGFR Targeting IR700-Related Photoimmunotherapy in Preventing Growth of Cancer Cells-A Systematic Review

EGFR靶向IR700相关光免疫疗法在预防癌细胞生长方面的疗效——系统评价

阅读:1

Abstract

INTRODUCTION: Research of Near-Infrared Photoimmunotherapy (NIR-PIT) related to human epidermal growth factor receptor (EGFR) in cancer is very popular in recent years. By destroying the cell membrane, NIR-PIT can kill cancer cells and prevent tumor development. By using a statistical method, our study aims to find out the suitable indices for evaluating the efficacy of EGFR-targeted NIR-PIT. METHODS: Exploring strategy: (mice OR vivo study OR animal model) AND (NIR-PIT OR near-infrared photoimmunotherapy OR photoimmunotherapy) AND (EGFR OR EGFR receptor) AND (cancer OR tumor). Including standard: ① Reports could obtain full text from 2014 to 2024. ② Reports using tumor volume as an index of outcome. ③ Reports using IR-700, NIR-PIT, and EGFR antigens. The exclusion criteria were as follows: ① Reports could not obtain the full text. ② Reports that did not use the index above. ③ Reports that did not use IR-700, NIR-PIT, or EGFR antigens. ④ Reports could not obtain concrete data from articles. RESULTS: Using the above standards, we finally acquired 20 articles that conformed to requests. In this analysis, tumor volume showed statistical meaning of differentiation between experimental and control groups. However, 50% survival did not show the statistical meaning in the analysis. DISCUSSION: Through analysis, we found that the NIR-PIT groups had obvious differences compared with the control groups in tumor volume. However, we did not find any difference in the survival rates between NIR-PIT and control groups. This may be due to the following reasons: ① the number of samples was insufficient. ② Other indices of survival rate were more suitable in this study than 50% survival rate. CONCLUSION: Compared with 50% survival rate, tumor volume may be better for evaluating the efficacy of NIR-PIT.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。